RxDoctor Payments Data

Bahattin Ergin, APRN

Psychiatric/Mental Health · Orlando, FLNPI 1386312023

Payments from drug & device makers

$3,076in general payments, 2019–2025

Across 82 payments — averaging $37.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corium, LLC$816
  • Neurocrine Biosciences, Inc.$454
  • Alkermes, Inc.$401
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$341
  • Vanda Pharmaceuticals Inc.$316
  • Neos Therapeutics, LP$195
  • plus $553 from 7 others

What the payments were for

  • Food & beverage$3,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,076 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$42,833
Medicare patients
149
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate17$59,496
VraylarCariprazine Hcl11$17,053
Paliperidone ErPaliperidone31$7,734
Asenapine Maleate15$1,485
Clozapine26$1,356
Hydroxyzine Hcl50$1,020
Buspirone Hcl63$894
Aripiprazole17$862
Olanzapine41$856
Lamotrigine30$755
Divalproex Sodium ErDivalproex Sodium14$666
Risperidone31$583
Trazodone Hcl40$534
Haloperidol20$518
Lorazepam39$511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$23$6314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →